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ABSTRACT
Dysregulated splicing is a common event in can-
cer even in the absence of mutations in the core
splicing machinery. The aberrant long non-coding
transcriptome constitutes an uncharacterized level
of regulation of post-transcriptional events in can-
cer. Here, we found that the stress-induced long
non-coding RNA (lncRNA), LINC02657 or LASTR
(lncRNA associated with SART3 regulation of splic-
ing), is upregulated in hypoxic breast cancer and
is essential for the growth of LASTR-positive triple-
negative breast tumors. LASTR is upregulated in sev-
eral types of epithelial cancers due to the activa-
tion of the stress-induced JNK/c-JUN pathway. Us-
ing a mass-spectrometry based approach, we iden-
tified the RNA-splicing factor SART3 as a LASTR-
interacting partner. We found that LASTR promotes
splicing efficiency by controlling SART3 association
with the U4 and U6 small nuclear ribonucleoproteins
(snRNP) during spliceosome recycling. Intron reten-
tion induced by LASTR depletion downregulates ex-
pression of essential genes, ultimately decreasing
the fitness of cancer cells.
INTRODUCTION
Hypoxia is a common micro-environmental feature that fa-
vors tumor progression and acquired drug resistance (1).
Long non-coding RNAs (lncRNAs) have recently emerged
as key players in hypoxia-driven cancer progression. lncR-
NAs represent a large and heterogeneous class of non-
coding RNAs broadly defined as RNA molecules longer
than 200 nucleotides without protein-coding potential.
Most lncRNAs are predominantly localized within the cell
nucleus, exhibit scarce evolutionary conservation (2), and
low expression levels (3). Although <1% of the identi-
fied human lncRNAs has been functionally characterized,
these particular lncRNAs participate in a variety of physio-
logical and pathological processes (4–6). Hypoxia-induced
lncRNAs play pivotal roles in regulating hypoxic responses
at chromatin, transcriptional, and post-transcriptional lev-
els by acting as either direct modulators of the hypoxia-
inducible factor (HIF) transcriptional cascade, or as HIF-
independent effectors. The aberrant expression of hypoxia-
induced lncRNAs is associated with aggressive tumor phe-
notypes, showing to be promising for future utility as a tu-
mor marker and/or therapeutic target (reviewed in (7)).
Recent studies have demonstrated that synthetic nucleic
acids represent a valuable approach for drug development
(8–10). Antisense oligonucleotides (ASOs), synthetic single-
stranded oligonucleotides that bind to the complemen-
tary cellular RNA sequences and block their expression,
have been successfully tested in preclinical in vivo mod-
els. ASO-mediated depletion of MALAT1 impedes tumor
growth and reduces lung metastases in a mouse model of
mammary carcinoma (11). ASO-based knockdown of the
lncRNA SAMMSON decreases survival of melanoma cells
in vitro and renders melanomas to be more sensitive to
MAPK-targeting therapeutics in patient-derived xenografts
(12). An alternative approach for lncRNA targeting could
be based on blocking lncRNA–protein interactions. As
an example, the small-molecule inhibitor ellipticine targets
HOTAIR–EZH2 interaction (13), thereby blocking epige-
netic changes that could drive cancer metastasis (14,15).
Here, we searched for hypoxia-regulated lncRNAs that
could serve as putative targets in breast cancer therapy.
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We found that the stress-induced lncRNA LINC02657,
which we named LASTR (lncRNA associated with SART3
regulation of splicing), is upregulated in hypoxic breast
cancer and is essential for the growth of triple-negative
breast cancer cells. LASTR depletion affects splicing ef-
ficiency leading to increased intron retention of essential
genes and decreased cancer cell fitness. Altogether, we pro-
pose LASTR inhibition as a novel therapeutic approach for
triple-negative breast cancer treatment.
MATERIALS AND METHODS
Plasmid constructs and GapmeRs
HA-tagged SART3, PURA, PURB, TRA2A, TRA2B
or FIP1L1 were cloned into pcDNA 3.1 (+) plasmid.
pGIPZ lentiviral vectors containing shControl, shHIF1
and shHIF2 were purchased from Open Biosystems.
shRNAs against SART3 or GFP were obtained from the
RNAi Consortium (TRC). Scramble shRNA or shRNA
against LASTR were cloned into Tet-pLKO-puro. Tet-
pLKO-puro was a gift from Dmitri Wiederschain (Addgene
plasmid #21915). Wild-type or mutated LASTR promoter
was cloned into the pGL4.20 (Promega) vector upstream of
the Firefly luciferase ORF sequence. GapmeRs were pur-
chased from Exiqon (Supplementary Table S1).
Cell culture
All cell lines were purchased from ATCC. MDA-MB-468
and MDA-MB-231 cell lines were cultured in DMEM–
Glutamax (Gibco) supplemented with 10% fetal bovine
serum (FBS) (Hyclone), 100 g/ml streptomycin and 100
U/ml penicillin (Gibco). BT-549 cells were cultured in
RPMI supplemented with 10% FBS (Hyclone), 100 g/ml
streptomycin and 100 U/ml penicillin (Gibco). MCF10A
cells were cultured in MEBM (Lonza) supplemented with
BPE, hEGF, insulin, hydrocortisone (Lonza) and 50 g
cholera toxin (Sigma-Aldrich).
Lentiviral infections were performed as described by
the RNAi Consortium (TRC). Infected cells were se-
lected using puromycin (InvivoGen). Plasmid transfection
was performed using FuGENE HD transfection reagent
(Promega); transfection of GapmeRs (10 nM) was per-
formed using Lipofectamine 2000 (Thermo Fisher Scien-
tific). The following drugs were used: SP600125 (Sigma-
Aldrich); doxycycline-hyclate (Sigma-Aldrich); doxoru-
bicin (Sigma-Aldrich).
Rapid amplification of cDNA ends
Rapid Amplification of cDNA Ends was performed us-
ing the SMARTer 5′/3′ RACE kit from Takara, accord-
ing to the manufacturer’s recommendations. Briefly, first
strand cDNA was synthesized by SMARTScribe Reverse
Transcriptase using a modified oligo (dT) primer, contain-
ing an additional sequence that is used as a primer bind-
ing site for downstream 3′ PCR reactions. On the 5′ end,
the SMARTer II A Oligonucleotide, containing several non-
templated residues, is annealed and serves as an additional
template for SMARTScribe RT and as a primer binding site
for downstream 5′ PCR reactions. A forward gene specific
primer for LASTR was designed for the 3′ end amplifica-
tion, and a reverse primer was designed for the 5′ end am-
plification.
Gene expression and splicing analyses
RNA from total cell lysates was isolated using the Nucle-
oSpin RNA kit (Machery Nagel). Nuclear and cytoplasmic
extracts were isolated using the Nuclei EZ prep kit (Sigma-
Aldrich). RNA extraction was then performed using the
Trizol/chloroform protocol. cDNA was reverse-transcribed
with the Sensifast cDNA synthesis kit (Bioline). Quantita-
tive real-time PCR was performed with the LightCycler 480
SYBR Green I Master reagent using the LightCycler 480
system (Roche). All primer sequences are reported in Sup-
plementary Table S1.
For RNA-seq analysis, RNA was extracted with the Nu-
cleospin RNA kit (Machery Nagel). RSEM (16) was used
to estimate gene abundance. Raw sequencing data were
aligned by STAR (17) with hg38 as the reference genome
and GENCODE v22 as gene annotation. Differentially ex-
pressed genes (baseMean > 50, |log2FoldChange| > 1, Padj
< 0.05) were determined by the R/Bioconductor package
DESeq2 (18). Biotypes of genes were annotated according
to GENCODE v22. The TPM (transcripts per million) val-
ues of differentially expressed genes were used to generate a
heatmap by the R/Bioconductor package ‘pheatmap’ using
the ‘Euclidean’ distance measure and ‘ward.D2’ clustering
method.
For the TCGA BRCA analysis, the hierarchical cluster-
ing analysis was performed using the hypoxia gene signa-
ture (19). RNAseq data for breast cancer samples were
downloaded from the TCGA GDC Data Portal. Cluster-
ing method ‘ward.D2’ and distance ‘Euclidean’ were used
to generate a dendrogram (20). The samples were separated
depending on the expression of the hypoxia gene signa-
ture. R/Bioconductor package DESeq2 was used to iden-
tify differentially expressed genes between hypoxia and nor-
moxia. The significance was determined by Padj < 0.05 and
|log2FoldChange| > 1.
Alternative splicing analysis was performed using the
R/Bioconductor package ASpli (21). Briefly, raw FASTQ
reads were mapped to the human genome using STAR with
default parameters. Exon skipping, intron retention, alter-
native 5′ splicing site, and alternative 3′ splicing site were
analyzed. To measure alternative splicing levels, PSI (per-
cent spliced-in or percent of inclusion) and PIR (percent of
intron retention) metrics were calculated for each sample.
Two types of exon–exon or exon–intron junction spanning
reads were counted: (i) reads that support sequence inclu-
sion, (ii) reads that support sequence exclusion. Only reads
of which >10% of the length overlapped with junctions were
counted. PIR/PSI was defined as the ratio between type 1
and the sum of types 1 and 2. To include low expression
genes in the analysis, we did not set a minimum number of
reads supporting a junction, but we excluded events with
a sum of exclusion reads and inclusion reads lower than 5.
For intron retention, we further checked the balance of two
exon–intron junctions by applying a binomial test to assess
if the ratio of the smaller one of two exon–intron junctions
reads and inclusion reads is 50%. Events with NA or 0 vari-
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ance were removed from the list. After obtaining the list
of spliced events, we performed a binomial test to test the
null-hypothesis that the proportion of upregulated splicing
events in one condition is 50%. The distribution of differ-
ence in PIR/PSI of spliced events between conditions are
shown by histograms. The mean of PIRs/PSIs was used to
represent the splicing level for one condition. Differentially
spliced events were determined by t-test (P < 0.05).
For splicing analysis in the TCGA samples, the BRCA
RNA-seq bam files were downloaded from the TCGA GDC
Data Portal. 25th and 75th percentiles were used to define
LASTR high and low expression. Intron retention analysis
in the TCGA samples was performed as described above,
but we only considered the intron retention events that were
detected in at least 10 TCGA samples of both the low and
high LASTR expression group.
Dual luciferase reporter assay
Firefly luciferase reporters containing the LASTR pro-
moter constructs and the pRL-TK Renilla luciferase re-
porter were transfected using FuGENE HD transfection
reagent (Promega). The luciferase activity was detected
using the Dual Luciferase Reporter Assay kit (Promega)
according to the manufacturer’s protocol. Luminescence
was measured using the VICTOR multilabel plate reader
(Perkin Elmer).
Cellular assays
2D colony formation was performed by seeding 1 × 103
cells (MDA-MB-231 and BT-549) or 2 × 103 cells (MDA-
MB-468) per well in a six-well plate. Colonies were fixed
and stained using 1% crystal violet in 35% methanol and
counted with the ColCount colony counter (Oxford Op-
tronix). Soft agar colony formation was performed by seed-
ing 1 × 104 cells in 0.35% agar (Sigma) on a 0.5% agar bot-
tom layer. The number of colonies was quantified using the
NIH ImageJ software. Cell growth was analyzed by seed-
ing 5000 cells/well in a 96-well plate. The growth was mea-
sured using the Cell Titer Glo kit (Promega) according to
the manufacture’s protocol.
For the radio-sensitization assay, cells transfected with
GapmeRs for 24 h, were exposed to increasing doses of ir-
radiation (2–6 Gy). After irradiation, cells were plated into
10 cm dishes. After 2–3 weeks cells were fixed with 2.5%
glutaraldehyde in PBS and stained with 0.4% crystal violet.
The colonies containing 50 or more cells were counted with
the ColCount colony counter (Oxford Optronix).
In vivo tumor xenografts
Xenograft experiments were approved by the Ethical Com-
mittee for Animal Experimentation (117/2016). Cells were
injected orthotopically into the mammary gland of immun-
odeficient NMRI nude mice. 5 × 105 cells were resuspended
in 100 l of a 1:1 mixture of PBS and Matrigel (Corn-
ing) and injected on both sides. Tumor volumes were mon-
itored every 2 days. Once the tumor volume reached 100
mm3, expression of shRNA against LASTR was achieved
by administering the mice drinking water supplemented
with 2 mg/ml doxycycline-hyclate (Sigma) in 10% sucrose
(Sigma). Drinking water with doxycycline was refreshed ev-
ery 48 h and protected from light. Mice bearing tumors ex-
cessing 1000 mm3 were sacrificed.
Immunohistochemistry and immunoblotting
All antibodies are reported in Supplementary Table S1.
IHC was performed on paraffin-embedded tumors. After
fixation in 4% paraformaldehyde (Bioconnect), 7 m paraf-
fin slides were rehydrated and treated with hydrogen perox-
ide. Antigen retrieval was induced by heat in Tris–EDTA
(pH 9). The sections were incubated with a specific anti-
body and diaminobenzidine (Dako) was used as a detection
method followed by hematoxylin counterstaining. Quantifi-
cation was done using the ImageJ IHC Profiler plugin (22).
For immunoblotting, cells were lysed and proteins were
subjected to SDS-PAGE (Invitrogen) and transferred to ni-
trocellulose membranes followed by immunoblotting with
specific antibodies. The signal was visualized with a chemi-
luminescence detection kit (Amersham Pharmacia Biotech)
using an automated digital developer.
Immunoprecipitation and RNA pull-down
Pull-down of in vitro transcribed LASTR was performed
as previously published (23). Briefly, in vitro transcribed
biotinylated sense or antisense LASTR transcripts were
synthesized using the AmpliScribe T7-Flash Biotin–RNA
Transcription Kit, according to the manufacturer’s instruc-
tions. Cells were lysed in ice-cold RNA Immunoprecipita-
tion (RIP) lysis buffer. Upon centrifugation at 15 000 g for
15 min at 4◦C, total protein extract was pre-cleared with
streptavidin agarose beads (Thermo Fisher Scientific). 1.5
mg of pre-cleared cell lysates was incubated with 10 pmol
of the biotinylated sense or antisense LASTR transcript
in RNA structure buffer (10 mM Tris–HCl pH 7.0, 100
mM KCl, 10 mM MgCl2) overnight at 4◦C. Streptavidin
agarose beads (Thermo Fisher Scientific) were then added
for 1 h at 4◦C. The beads were washed three times with
ice-cold 1× complete NT2 (50 mM Tris–HCl pH 7.4, 150
mM NaCl, 1 mM MgCl2, 20 mM EDTA, 0.05% NP-40
and 1 mM TPEC, 100 U/ml RNase inhibitor (Roche), pro-
tease inhibitor, PhosSTOP (Roche)) buffer, three times with
trypsin digestion buffer (20 mM Tris–HCl, pH 8.0 and 2
mM CaCl2), and used for mass spectrometry (MS) analy-
sis.
Pull-down of endogenous LASTR was performed as
previously described in (12) with few modifications (for
a detailed step-by-step protocol, refer to Barra et al.
‘M(R)apping RNA–protein interactions’, Methods Mol
Biol, 2020 (in press)). Briefly, 100 g of streptavidin mag-
netic beads were incubated overnight at 4◦C with 900 pmol
of biotinylated LASTR sense or antisense RNA antisense
purification (RAP) probes (Biosearch Technologies, Probe
sequences are shown in Supplementary Table S1). 4 ×
107 cells were washed twice in PBS and fractionated us-
ing the Nuclei EZ prep (Sigma-Aldrich) according to the
manufacturer’s instructions. Nuclei were lysed in 3.5 ml
of pull-down buffer (20 mM Tris–HCl pH 8.0, 200 mM
NaCl, 2.5 mM MgCl2, 0.05% Triton X-100 in DEPC wa-
ter) supplemented with a cocktail of protease inhibitors
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(Halt Protease and Phosphatase Inhibitor Single-Use Cock-
tail (100×) – Thermo Fisher), 1 mM dithiothreitol and
60 U/ml of SUPERase In RNase Inhibitor (Invitrogen).
Lysates were incubated with the beads coupled to the RAP
probes at 4◦C for 3 h. Samples were then washed five times
in pull-down buffer and then divided in two, to elute ei-
ther proteins or RNA. RNA was eluted from the beads us-
ing Trizol/chlorophorm and precipitated with isopropanol.
The purified RNA was treated with DNAse and stored at
−80◦C. The RAP efficiency was estimated by RT-qPCR us-
ing 0.5 g of RNA for the inputs and equal elution volumes
for each pull-down sample.
For RNA immunoprecipitation (RIP), cells were washed
with ice-cold PBS and lysed in polysome buffer (20 mM
Tris–HCl pH 8, 200 mM NaCl, 2.5 mM MgCl2, 0.5% Tri-
ton X-100, 60 U/ml SUPERase In RNase Inhibitor (In-
vitrogen), 1 mM dithiothreitol (DTT) and 1× Halt Pro-
tease and Phosphatase Inhibitor Single-Use Cocktail (Life
Technologies)) and incubated on ice for 15 min. The sol-
uble fraction obtained by centrifugation at 3220 g for 15
min at 4◦C was precleared with 20 l of Pierce protein A/G
magnetic beads (Thermo Fisher Scientific) for 1 h at 4◦C.
A fraction of the lysate was used for RNA extraction using
Trizol/chloroform. The rest of the sample was analysed by
immunoblotting. The lysates were incubated with 5 g of
antibody against SART3 or IgG specific overnight at 4◦C,
and then with 50 l of Pierce protein A/G magnetic beads
for 3 h at 4◦C. Beads were then washed four times with
polysome buffer and divided in two parts. One fraction was
used to confirm immunoprecipitation by immunoblotting,
and the other fraction was used for RNA extraction using
Trizol/chloroform and isopropanol precipitation.
Expression of the genes of interest was calculated using
the Ct method, correcting the Ct values by their dilution
factor. The Ct value of the input was subtracted from the Ct
values of the RIP/RAP, and this normalized Ct value was
used to calculate the yield as % of input by the following
equation:
% input = 2−Ct × 100%
Fluorescent in situ hybridization (FISH)
Cells were plated on an eight-well chamber glass slide
(Nalge Nunc International), fixed with 4% paraformalde-
hyde and permeabilized in 70% ethanol. Hybridization
was carried out using a pool of 27 FISH probes designed
against LASTR using the Stellaris probe designer software
(Biosearch Technologies). The incubation was performed
overnight at 37◦C in 2× SSC, 10% formamide and 10% dex-
tran. Cells were counterstained with DAPI and images were
obtained by using a confocal Nikon C2 microscope (VIB
Bioimaging Core).
Chromatin immunoprecipitation
ChIP was performed using the Magna Chip kit (Milli-
pore) following manufacturer’s protocol. Briefly, cells were
fixed in 1% formaldehyde, lysed and subjected to differen-
tial centrifugation to extract nuclei. Nuclei were then lysed
and cross-linked chromatin was sonicated to obtain op-
timal DNA fragment size. Immunoprecipitation was per-
formed by incubating 2 g of DNA material with 3 g
of antibody against c-JUN and phosphorylated c-JUN
(Ser73) or control IgG and protein A/G coupled magnetic
beads, overnight at 4◦C. Elution, reversal of cross-linking
of protein/DNA complexes and DNA extraction was done
following the kit’s protocol. qPCR analysis was performed
using primers specific to the LASTR promoter region (Sup-
plementary Table S1).
RNA native gel electrophoresis
The U4/U6 complex formation was analyzed by perform-
ing a native RNA gel electrophoresis after in solution hy-
bridization as described in (24). Briefly, a U6snRNA flu-
orescent probe (Supplementary Table S1) was designed as
described in (24). 0.1 pmol of the U6snRNA probe was in-
cubated with 1 l of nuclear RNA (3 g/l) in the pres-
ence of hybridization buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1 mM EDTA) for 15 min at 37◦C. The reaction was
stopped by placing the samples on dry ice. 1 l of 5× Hi-
Density TBE sample buffer was added (Novex, Invitrogen).
The samples were then subjected to a non-denaturing 8%
TBE gel (Novex, Invitrogen) in TBE running buffer (Novex,
Invitrogen) at 250 V on ice. After electrophoresis, the gel
was developed using a Typhoon biomolecular imager. Sub-
sequent staining of the gel with Midori Green was used to
control the loading.
Mass spectrometry analysis
For the shotgun analysis after RNA immunoprecipitation,
washed beads were re-suspended in 150 l digestion buffer
and incubated for 4 h with 1 g of trypsin (Promega)
at 37◦C. Beads were removed, another 1 g of trypsin
was added and proteins were further digested overnight
at 37◦C. Peptides were purified on Omix C18 tips (Agi-
lent), dried and re-dissolved in 20 l of 0.1% trifluoroacetic
acid in water/acetonitrile (98:2, v/v) of which 2 l was in-
jected for LC–MS/MS analysis on an Ultimate 3000 RSLC-
nano system (Thermo) in line connected to a Q Exactive
mass spectrometer (Thermo). Trapping was performed at
10 l/min for 4 min in solvent A (0.1% formic acid in
water/acetonitrile (98:2, v/v)) on a 100 m internal diam-
eter (I.D.) × 20 mm trapping column (5 m beads, C18
Reprosil-HD, Dr Maisch, Germany) and the sample was
loaded on a reverse-phase column (made in-house, 75 m
I.D. × 150 mm, 3 m beads C18 Reprosil-HD, Dr Maisch).
Peptides were eluted by a linear increase from 2 to 55% sol-
vent B (0.08% formic acid in water/acetonitrile (2:8, v/v))
over 120 min at a constant flow rate of 300 nl/min. The mass
spectrometer was operated in data-dependent mode, auto-
matically switching between MS and MS/MS acquisition.
Full-scan MS spectra (400–2000 m/z) were acquired at a
resolution of 70 000 in the orbitrap analyzer after accumu-
lation to a target value of 3 000 000. The ten (LASTR) or
five (SART3) most intense ions above a threshold value of
17 000 or 13 000 were isolated (window of 2.0 Th) for frag-
mentation at a normalized collision energy of 25% after fill-
ing the trap at a target value of 50 000 for maximum 60 or
80 ms, respectively. MS/MS spectra (200–2000 m/z) were
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acquired at a resolution of 17 500 in the orbitrap analyzer.
The S-lens RF level was set at 50, and we excluded precur-
sor ions with single, unassigned and charge states above five
from fragmentation selection. Data analysis was performed
with MaxQuant (version 1.5.3.30) using the Andromeda
search engine with default search settings including a false
discovery rate set at 1% on both the peptide and protein
level. Spectra were searched against the human proteins in
the SwissProt database, supplemented with the sequences
of protein A/G. The mass tolerance for precursor and frag-
ment ions were set to 4.5 and 20 ppm, respectively, during
the main search. Enzyme specificity was set as C-terminal to
arginine and lysine, also allowing cleavage at proline bonds
with a maximum of two missed cleavages. Only proteins
with at least one unique or razor peptide were retained lead-
ing to the identification of 959 (LASTR) and 252 proteins
(SART3). Proteins were quantified by the MaxLFQ algo-
rithm integrated in the MaxQuant software. A minimum ra-
tio count of two unique or razor peptides was required for
quantification. Further data analysis was performed with
the Perseus software (version 1.5.3.0) after loading the pro-
tein groups file from MaxQuant. Proteins only identified
by site and reverse database hits were removed, LFQ inten-
sity values were log2 transformed and replicate samples of
both conditions were grouped. In the SART3 experiment,
protein intensity values in each replicate were normalized
based on the expression level of the SART3 bait protein.
Proteins with less than three valid values in at least one
group were removed and missing values were imputed from
a normal distribution around the detection limit. Then, a
T-test was performed for pairwise comparison of both con-
ditions. For each protein, the log2 (LASTR sense/LASTR
antisense (LASTR) or LASTR GapmeR1/Scramble Gap-
meR (SART3)) fold change value is indicated on the X-axis,
while the statistical significance (−log P value) is indicated
on the Y-axis. Proteins outside the curved lines, set by an
FDR value of 0.05 and an S0 value of 1 (LASTR) or 1.5
(SART3) in the Perseus software, are considered as putative
targets.
For the shotgun analysis on whole cell lysates, frozen cell
pellets were dissolved in 1 ml lysis buffer (20 mM HEPES
pH 8.0, 8 M urea) and lysis was performed by sonication
at high intensity with 10 cycles of 30 s in a water bath at
10◦C using a Diagenode Bioruptor Plus. After centrifuga-
tion for 15 min at 20 000 × g at room temperature to re-
move insoluble components, proteins were reduced by ad-
dition of 5 mM DTT and incubation for 30 min at 55◦C
and then alkylated by addition of 10 mM iodoacetamide
for 15 min at room temperature in the dark. The protein
concentration was measured using a Bradford assay (Bio-
Rad) and from each sample 200 g of protein was used to
continue the protocol. Samples were further diluted with 20
mM HEPES pH 8.0 to a final urea concentration of 4 M and
proteins were digested with 2 g of LysC (Wako) (1/100,
w/w) for 4 h at 37◦C. Samples were again diluted to 2 M of
urea and digested with 2 g of trypsin (Promega) (1/100,
w/w) overnight at 37◦C. The resulting peptide mixture was
acidified by addition of 1% trifluoroacetic acid (TFA) and
after 15 min incubation on ice, samples were centrifuged for
15 min at 1780 × g at room temperature to remove insoluble
components. Next, peptides were purified on SampliQ SPE
C18 cartridges (Agilent). Columns were first washed with
1 ml of 100% acetonitrile (ACN) and pre-equilibrated with
3 ml of solvent A (0.1% TFA in water/ACN (98:2, v/v))
before samples were loaded on the column. After peptide
binding, the column was washed again with 2 ml of solvent
A and peptides were eluted twice with 75 l of elution buffer
(0.1% TFA in water/ACN (40:60, v/v)). Purified peptides
were dried, re-dissolved in solvent A and ∼3 g of each
sample was injected for LC–MS/MS analysis on an Ulti-
mate 3000 RSLCnano system (Thermo) in-line connected
to a Q Exactive HF mass spectrometer (Thermo) equipped
with a Nanospray Flex Ion source (Thermo). Trapping was
performed at 10 l/min for 4 min in solvent A on a 20 mm
trapping column (made in-house, 100 m internal diame-
ter (I.D.), 5 m beads, C18 Reprosil-HD, Dr Maisch, Ger-
many) and the sample was loaded on a 200 cm long micro
pillar array column (PharmaFluidics) with C18-endcapped
functionality mounted in the Ultimate 3000’s column oven
at 50◦C. For proper ionization, a fused silica PicoTip emit-
ter (10 m inner diameter) (New Objective) was connected
to the PAC™ outlet union and a grounded connection
was provided to this union. Peptides were eluted by a non-
linear increase from 1 to 55% MS solvent B (0.1% FA in
water/ACN (2:8, v/v)) over 145 min, first at a flow rate of
750 nl/min, then at 300 nl/min, followed by a 15-min wash
reaching 99% MS solvent B and re-equilibration with MS
solvent A (0.1% FA in water/ACN (2:8, v/v)). The mass
spectrometer was operated in data-dependent mode, auto-
matically switching between MS and MS/MS acquisition
for the 16 most abundant ion peaks per MS spectrum. Full-
scan MS spectra (375–1500 m/z) were acquired at a resolu-
tion of 60 000 in the orbitrap analyzer after accumulation to
a target value of 3 000 000. The 16 most intense ions above
a threshold value of 13 000 were isolated (window of 1.5
Th) for fragmentation at a normalized collision energy of
28% after filling the trap at a target value of 100 000 for
maximum 80 ms. MS/MS spectra (200–2000 m/z) were ac-
quired at a resolution of 15 000 in the orbitrap analyzer.
The S-lens RF level was set at 50 and we excluded precur-
sor ions with single, unassigned and >7 charge states from
fragmentation selection. Data analysis was performed with
MaxQuant (version 1.6.2.6) using the Andromeda search
engine with default search settings including a false discov-
ery rate set at 1% on both the peptide and protein level.
Spectra were searched against the human proteins in the
Swiss-Prot database. The mass tolerance for precursor and
fragment ions was set to 4.5 and 20 ppm. Enzyme speci-
ficity was set as C-terminal to arginine and lysine, also al-
lowing cleavage at proline bonds with a maximum of two
missed cleavages. Matching between runs was enabled with
a matching time window of 1.5 min and an alignment time
window of 20 min. Only proteins with at least one unique or
razor peptide were retained leading to the identification of
5528 proteins. Proteins were quantified by the MaxLFQ al-
gorithm integrated in the MaxQuant software. A minimum
ratio count of two unique or razor peptides was required for
quantification. Further data analysis was performed with
the Perseus software (version 1.6.2.1) after loading the pro-
tein groups file from MaxQuant. Proteins with less than
three valid values in at least one group were removed and
missing values were imputed from a normal distribution
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around the detection limit leading to a list of 2940 quan-
tified proteins used for further data analysis. Differentially
expressed proteins were identified by a t-test.
RESULTS
Hypoxia-induced lncRNA LASTR is upregulated in epithe-
lial cancer
Although hypoxia can occur at different stages of breast
tumorigenesis (25,26), it is not clear how hypoxia affects
cells in the earlier stages of transformation. To identify non-
coding transcripts involved in the cellular adaptation to
limited oxygen supply in early pre-malignant lesions, we
used the non-tumorigenic MCF10A breast epithelial cell
line to replicate conditions found within early hyperplas-
tic breast lesions. As MCF10A cells are non-transformed,
this setup allows us to study the effects of hypoxia indepen-
dently from the contribution of cancer-associated genetic
and epigenetic changes. To gain a global overview of the
transcriptional response to hypoxia, we assessed the expres-
sion profiles of MCF10A cells cultured under normoxic or
hypoxic conditions. The RNA sequencing (RNAseq) analy-
sis identified 45 lncRNAs that were upregulated by hypoxia
in MCF10A cells (Figure 1A). Several of the identified non-
coding RNAs, such as MALAT1, NEAT1 and LUCAT1
have been previously reported as hypoxia-induced lncRNAs
(27,28).
We next assessed which of these lncRNAs were also over-
expressed in hypoxic breast cancers. We stratified The Can-
cer Genome Atlas (TCGA) breast cancer patients accord-
ing to their hypoxia gene signature (19) (Supplementary
Figure S1A) and identified 742 lncRNAs that were differ-
entially expressed in hypoxic versus normoxic tumors. Ex-
pression of 17 out of 45 lncRNAs, upregulated by hypoxia
in MCF10A cells was also altered in the hypoxic TCGA
breast cancer samples (Figure 1B). For further studies, we
decided to focus on the intergenic lncRNA LINC02657,
which we named LASTR, as it was described in the atlas
of human lncRNAs from the FANTOM5 project (29) (Fig-
ure 1C, Supplementary Figure S1B); does not overlap with
other genes; and was one the most abundantly expressed
lncRNAs in MCF10A cells and breast cancer cell lines
(Supplementary Figure S3C). We confirmed that hypoxic
TCGA BRCA tumors showed higher levels of LASTR
expression (Figure 1D). An RT-qPCR analysis validated
that LASTR was upregulated by hypoxia in MCF10A cells
along with hypoxia-induced genes, LOX and NFIL3 (30)
(Figure 1E). We also observed that hypoxia increased ex-
pression of LASTR in the triple-negative MDA-MB-231
and BT-549 cell lines, even though the hypoxic response was
less significant in breast cancer cells when compared to non-
tumorigenic MCF10A cells (Figure 1E).
The LASTR gene is located on the minus strand of chro-
mosome 10, flanked by CALML3 and ASB13 loci, and has
three isoforms (Figure 1C and Figure S1B). Consistently
with the FANTOM5 data, RT-qPCR analysis demon-
strated that the shortest LASTR-1 isoform was the most
abundant (Supplementary Figure S1D). A RACE analy-
sis revealed that the LASTR transcript was 704 nucleotides
long, composed of two exons, and polyadenylated (Fig-
ure 1C). DeepBase v2.0 analysis (http://biocenter.sysu.edu.
cn/deepBase/) of the LASTR-1 evolutional pattern showed
that it is a primate specific lncRNA (Supplementary Figure
S1D), whereas ORF Finder analysis (www.ncbi.nlm.nih.
gov/gorf/gorf.html) revealed that the shortest LASTR tran-
script is composed of non-translatable regions for at least
46% of its length. Consistent with this observation, Pep-
Bank search failed to identify any human peptide match-
ing any ORF in this locus, and PhyloCSF and CPAT soft-
ware further confirmed that LASTR does not have protein-
coding potential (PhyloCSF score < 0.364 and CPAT Fick-
ett TESTCODE statistic P < 0.01).
Analysis of LASTR expression in the TCGA BRCA co-
hort demonstrated that LASTR was overexpressed in all
breast cancer subtypes when compared to normal breast
tissue. The highest levels of LASTR upregulation were ob-
served in the most aggressive HER2-positive and triple-
negative or basal breast cancers (Figure 1F). LASTR ex-
pression did not correlate with stages of breast cancer (Fig-
ure 1G), suggesting that LASTR overexpression is a rel-
atively early event during breast cancer progression. Fur-
ther analysis of the TCGA datasets unveiled that LASTR
was also significantly upregulated in several types of ep-
ithelial cancers (Figure 1H). Moreover, the survival anal-
yses showed that high levels of LASTR expression were as-
sociated with poor survival of patients with renal clear cell
carcinoma and lung adenocarcinoma (Supplementary Fig-
ure S1F, G). Altogether, these findings suggest that LASTR
might be associated with cancer development.
LASTR expression is induced by the stress-activated JNK/c-
JUN pathway
Hypoxia-responsive lncRNAs can be categorized as HIF-
dependent and HIF-independent (7). HIFs could directly
regulate lncRNAs at the transcriptional level through hy-
poxia response elements (HREs). However, in silico pre-
diction and ENCODE ChIP (chromatin immunoprecipita-
tion) analyses did not reveal HREs in the LASTR promoter.
Concordantly, suppression of either HIF1 or HIF2 did
not significantly affect induction of LASTR under hypoxic
conditions (Supplementary Figure S2A, B), indicating that
LASTR upregulation by hypoxia is HIF-independent.
The transcription factor ChIPseq data from ENCODE
revealed binding of several transcription factors upstream
of the LASTR transcription start site. However, only c-
JUN showed consistent binding to the LASTR promoter
in three different cancer cell lines, K562, HelA-S3 and
A549. The ChIPBase depository (http://deepbase.sysu.edu.
cn/chipbase/) also demonstrated the presence of the c-JUN
binding site in a close proximity to the LASTR transcription
start site in the breast cancer cell line BT-549. Moreover,
the c-JUN canonical motif sequence (TGACTCACC) is lo-
cated ∼90 nucleotides upstream of the LASTR transcrip-
tion start site (Figure 2A). We also found a higher expres-
sion of LASTR in the TCGA BRCA patients with higher
levels of c-JUN phosphorylated at Ser73 (Figure 2B). Alto-
gether, these observations suggest that LASTR expression
might be regulated by the JNK/c-JUN pathway.
The phosphorylation of c-JUN at Ser63 and Ser73
by stress-induced c-JUN-NH2-terminal kinase (JNK) pre-
vents ubiquitin-dependent degradation of c-JUN and po-


























Figure 1. The lncRNA LASTR is commonly upregulated in epithelial cancers. (A) Heatmap showing differentially expressed lncRNAs in normoxic and
hypoxic (1% O2, 48 h) MCF10A cells as determined by RNA-seq. The scale bar indicates the z-score of transcripts per million (TPM). (B) Overlap
between hypoxia-associated lncRNAs in hypoxic TCGA BRCA tumors and hypoxic MCF10A cells. (C) Graphical representation of the zoomed LASTR
genomic region along with LASTR CAGE expression data of the LASTR-1 isoform obtained from the FANTOM5 project and the results from a 5′ and 3′
RACE analysis in MCF10A and MDA-MB-231 cells. (D) Boxplot showing LASTR expression in the TCGA BRCA patients stratified by hypoxia status
as described in (19). n = number of patients. (E) RT-qPCR analysis of mRNA expression analysis in breast cells cultured under normoxic and hypoxic (1%
O2) conditions. Data are presented as mean ± s.e.m.; P-values were determined by two-sided t-tests, n = 3. (F) LASTR expression in the TCGA BRCA
patients stratified according to their PAM50 status. P-values were determined by a two-sided t-test. n = number of patients. (G) LASTR expression in the
TCGA BRCA patients stratified by tumor stages (T1–T4). n = number of patients. (H) LASTR expression in the TCGA tumor samples. Kidney Renal
Clear Cell Carcinoma (KIRC), Head and Neck Squamous Cell Carcinoma (HNSC), Lung Squamous Cell Carcinoma (LUSC), Lung Adenocarcinoma
(LUAD) and Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC). P-values were determined by two-sided t-tests. (D, F, G,
H) Boxplots show the 25th and 75th percentile of values. The horizontal line indicates the median expression value with whiskers expanding to 1.5 times
the interquartile range of the data. P-values were determined by two-sided t-tests.
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Figure 2. Stress induces expression of the lncRNA LASTR in a JNK/c-JUN-dependent manner. (A) Graphical representation of the LASTR-1 promoter
region along with the ENCODE CHIP-seq data from Hela-S3, HUVECs and K562 cells summarized in a black bar. The red bar shows a canonical c-JUN
binding site. (B) Boxplot showing LASTR expression in TCGA BRCA patients stratified by levels of c-JUN phosphorylated at Ser73. Median was used
to define high and low levels of phospho-c-JUN. P-value was determined by a Mann–Whitney test. n = number of patients. (C) Immunoblot analysis
of phosphorylated and total c-JUN in MCF10A cells treated with DMSO or SP600125 (20 M, 18 h). (D) RT-qPCR analysis of LASTR expression in
MCF10A cells treated with DMSO or SP600125 (20 M) for the indicated time periods, n = 3. (E) Immunoblot analysis of phosphorylated and total c-JUN
in MCF10A cells treated with DMSO or SP600125 (20 M, 18 h) under normoxia or hypoxia (1% O2, 16 h). (F) RT-qPCR analysis of LASTR expression
in normoxic or hypoxic (1% O2, 16 h) MCF10A cells treated for 18 h with DMSO or SP600125 (20 M), n = 3. (G) Wild-type LASTR and mutant
LASTR promoter activity in MCF10A cells treated with DMSO or SP600125 (20 M, 18 h) under normoxia or hypoxia (1% O2, 16 h) as determined by a
dual-luciferase reporter assay. P-value was determined by a one-way ANOVA test, n = 3. (H) Immunoblot analysis of phosphorylated and total c-JUN in
MCF10A cells treated for 1 h with DMSO or doxorubicin (0.3 M). (I) RT-qPCR analysis of LASTR expression in MCF10A cells treated for 24 h with
DMSO or doxorubicin (0.3 M). n = 3. (J) RT-qPCR analysis of LASTR expression in MCF10A cells treated for 24 h with doxorubicin (0.3 M), or the
combination of doxorubicin (0.3 M) and SP600125 (20 M), n = 3 (K) qPCR analysis of LASTR promoter recovered in ChIP assays conducted with the
indicated antibodies. Chromatin precipitation was performed using MCF10A cells under normoxia or hypoxia (1% O2, 16 h), n = 3. (D, F, I, J, K) Data
are presented as mean ± s.e.m.; P-values were determined by two-sided t-tests.
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tentiates its activity (31–33). Therefore, we tested how phar-
macological blocking of JNK by the SP600125 inhibitor af-
fected LASTR expression. We found that treatment with
SP600125 not only reduced levels of phosphorylated and
total c-JUN as expected, but also inhibited LASTR expres-
sion (Figure 2C, D). On the other hand, hypoxia led to in-
creased phosphorylation at Ser63 and stability of c-JUN, as
well as increased expression of LASTR, whereas JNK inhi-
bition blocked hypoxia-mediated LASTR induction (Fig-
ure 2E, F).
We next assessed the activity of a 315 bp DNA frag-
ment of the LASTR promoter, which overlaps with the
predicted c-JUN binding site (Figure 2A), by cloning this
fragment into the pGL4 luciferase reporter plasmid. We
found that hypoxia triggered the LASTR promoter activity,
whereas SP600125 treatment suppressed its activity (Fig-
ure 2G). The effect of the JNK inhibition on LASTR pro-
moter activity was even more significant under hypoxic con-
ditions (Figure 2G). Furthermore, mutations in the canoni-
cal c-JUN binding motif abolished both basal and hypoxia-
induced activity of the LASTR promoter (Figure 2G).
Taken together, these results indicate that LASTR upreg-
ulation by hypoxia is JNK/c-JUN-dependent. Given that
DNA damage is also known to activate the JNK/c-JUN
signaling pathway (34), we also explored whether the DNA-
damaging drug doxorubicin could also induce LASTR ex-
pression in a JNK/c-JUN-dependent manner. Consistent
with previous reports, we found that doxorubicin treatment
increased levels of phosphorylated and total c-JUN (Fig-
ure 2H). Moreover, doxorubicin increased LASTR expres-
sion in MCF10A cells in a JNK-dependent manner (Figure
2I, J), indicating that doxorubicin treatment activates the
JNK/c-JUN pathway and promotes LASTR expression.
To validate c-JUN binding to the LASTR genomic re-
gion, we performed a ChIP-qPCR using antibodies against
total c-JUN or c-JUN phosphorylated at Ser73. Both c-
JUN and phospho-c-JUN showed a stronger binding to
the LASTR promoter region in response to hypoxia (Fig-
ure 2K). Taken together, these results indicate that LASTR
expression is triggered by the stress-activated JNK/c-JUN
pathway, suggesting that overexpression of LASTR in hu-
man cancers could be caused by upregulation of c-JUN ac-
tivity, a process commonly occurring in epithelial cancer.
LASTR depletion affects splicing efficiency by regulating the
function of the RNA-splicing factor SART3
To assess the cellular function of the lncRNA LASTR, we
first examined its subcellular localization by performing cel-
lular fractionation. Consistent with previous reports (35),
the lncRNA MALAT1 was strictly retained in the nucleus.
On the other hand, we found that LASTR was predomi-
nantly localized in the nucleus although it could be also de-
tected in the cytosolic fraction (Figure 3A). This finding was
confirmed by performing LASTR-Fluorescent In Situ Hy-
bridization (LASTR-FISH). LASTR showed a diffused nu-
clear pattern of expression with an enrichment in nucleoli-
like structures (Figure 3B).
As multiple lncRNAs have been shown to act in a com-
plex with proteins (36), we screened for putative protein in-
teractors of LASTR. We incubated in vitro transcribed bi-
otinylated LASTR sense or antisense RNA strands with
MCF10A protein extracts. Subsequently, the lncRNA–
protein complexes were pulled down using streptavidin
beads. Quantitative mass spectrometry (MS) analysis iden-
tified several proteins enriched in the LASTR sense fraction
(Figure 3C).
We focused on nuclear proteins for further characteriza-
tion, as LASTR was mostly observed in the nucleus (Fig-
ure 3A, B). We incubated in vitro transcribed biotinylated
LASTR sense or antisense RNA strands with MCF10A
cell lysates overexpressing the different HA-tagged candi-
dates. The lncRNA–protein complexes were pulled down
using streptavidin beads followed by immunoblotting with
anti-HA antibody. SART3 was the best hit as it showed
the strongest enrichment with the LASTR sense strand and
no detectable interaction with the antisense strand (Figure
3D).
Previous reports demonstrated that SART3 interacts
transiently with the U6 and U4/U6 small nuclear ribonu-
cleoprotein (RNP) particles and promotes the assembly
of the U4/U6snRNP complex (snRNPs) (37,38). In fact,
we detected a significant enrichment for U6 snRNA when
we pulled down endogenous SART3. LASTR was also
present in the SART3 pull-downs, whereas we did not de-
tect any enrichment for the more abundant nuclear lncR-
NAs, MALAT1 and NEAT1 (Figure 3E). Using an RNA
affinity purification (RAP), we further validated the bind-
ing of LASTR to SART3. Endogenous LASTR was pulled
down with biotinylated Stellaris probes specific for either
the sense, or antisense transcript of LASTR. Whereas we
detected SART3 in the LASTR pull-downs, we did not
observe an enrichment of the abundant nuclear protein
NONO (Figure 3F). Altogether, our results indicate that
LASTR (lncRNA associated with SART3 regulation of
splicing) is a nuclear lncRNA that forms a complex with
the SART3 protein.
Although we observed a strong binding of SART3 to
U6 snRNA in the RNA immunoprecipitation (RIP) exper-
iment (Figure 3E), we could not detect any U6 snRNA in-
teraction with SART3 bound to LASTR, suggesting that
LASTR might affect SART3 association with the splicing
machinery (Figure 3F). To test this idea, we purified SART3
complexes isolated from MCF10A cells treated with ei-
ther Scramble, or LASTR specific GapmeR1 and analyzed
the SART3 interactome by MS (Figure 3G, Supplementary
Figure S2C). The proteins identified in the SART3 immuno-
precipitates considerably overlapped (P-value < 2.2e−16 as
determined by a Fisher’s exact test) with the previously re-
ported SART3 interactome, validating our assay (39). The
analysis of proteins differentially interacting with SART3
demonstrated that treatment with the LASTR GapmeR1
increased the interaction of SART3 with the components
of U4snRNP, SNRPD1, SNRPD2 and SNRPD3 (Figure
3G). On the other hand, LASTR depletion did not affect
SART3 binding to the components of the U6snRNP, such
as LSM2–8 proteins, PRPF31, and PRPF4 (40,41). Con-
cordantly with the MS results, LASTR depletion increased
association of SART3 with U4snRNA, but did not affect
the interaction of SART3 with U6snRNA (Figure 3H). We
also found that suppression of LASTR did not affect the
formation of the U4/U6 complex (Supplementary Figure












































































































































































































































Figure 3. LASTR modulates SART3 interactions with U4snRNP and U6snRNP. (A) Subcellular localization of LASTR. LASTR expression was analyzed
by RT-qPCR in cellular fractions of MCF10A. Data are presented as mean ± s.e.m.; P-values were determined by two-tailed t-tests, n = 3. (B) LASTR
fluorescent in situ hybridization of MCF10A. LASTR-specific probe signals are shown in red. Scale bar, 10 m. (C) Volcano plot showing LASTR interac-
tors from triplicate pull-downs of total protein extracts from MCF10A cells. Proteins interacting with biotinylated LASTR sense or antisense strands were
determined by MS. Putative nuclear interactors of LASTR are shown in red. (D) Validation of LASTR nuclear interactors. Biotinylated sense or antisense
LASTR was used for pull-down from MCF10A cells ectopically expressing HA-tagged candidate proteins. The pulldown was followed by immunoblotting
using anti-HA antibody. (E) SART3 was immunoprecipitated from MCF10A total protein extracts using anti-SART3 antibody. The presence of SART3
in the immunoprecipitate was detected by immunoblotting, the presence of the indicated non-coding RNAs in the SART3 immunoprecipitate was deter-
mined by RT-qPCR analysis. Data are presented as mean ± s.e.m.; P-values were determined by two-tailed t-test, n = 3. (F) LASTR was pulled down from
MCF10A cell lysates using biotinylated Stellaris probes. Stellaris probes against antisense LASTR were used as a negative control. SART3 and NONO
were detected in the LASTR pull-downs by immunoblotting. (G) Volcano plot of SART3 interactors from triplicate pull-downs of total protein extracts
from MCF10A cells treated with Scramble GapmeR or LASTR GapmeR1. U4-associated proteins are shown in red; U6-associated proteins are shown in
blue. (H) Presence of U4snRNA and U6snRNA in SART3 immunoprecipitates as detected by RT-qPCR. SART3 immunoprecipitated from total protein
extracts of MCF10A cells treated with Scramble GapmeR or LASTR GapmeR1 using anti-SART3 antibody. Data are presented as mean ± s.e.m.; P-values
were determined by two-tailed t-tests, n = 3.
2512 Nucleic Acids Research, 2020, Vol. 48, No. 5
S2E). Together, these results suggest that LASTR does not
affect the formation of the U4/U6 complex, but could pro-
mote SART3 dissociation from the U4/U6snRNP complex
during the splicesome cycle.
To examine the impact of LASTR on splicing, we per-
formed transcriptome analysis using a recently developed
R package ‘ASpli’ for an integrative splicing analysis. AS-
pli allows an unbiased evaluation of annotated and novel
splicing events and calculates the differences in the percent-
age of exon inclusion (PSI) and percentage of intron reten-
tion (PIR) (Supplementary Figure S3A). We first utilized
ASpli to assess the effect of SART3 suppression on splicing
(Supplementary Figure S3B). We found that depletion of
SART3 in MDA-MB-231 breast cancer cells using two dif-
ferent shRNAs led to increased intron retention and exon
skipping (Figure 4A; Supplementary Figure S3C), whereas
we did not observe a consistent alteration in alternative 5′
and 3′ splicing (Supplementary Figure S3D, E). These re-
sults indicate that SART3 suppression reduces the efficiency
of pre-mRNA processing, but does not alter alternative 5′
and 3′ splicing.
Similar to SART3 suppression, we observed increased in-
tron retention and exon skipping in MCF10A after trans-
fection with LASTR-specific GapmeRs (Figure 4B) and
in MDA-MB-231 cells upon induction of three different
shRNAs targeting LASTR (Figure 4C–F; Supplementary
Figure S4A, B). On the other hand, LASTR suppression
did not affect the usage of alternative 5′ and 3′ splice
sites (Supplementary Figure S4C, D). We also assessed
the role of LASTR in splicing regulation under hypoxic
conditions, which is known to affect alternative splicing
(42,43). We found that hypoxia altered both splicing effi-
ciency and alternative splicing in MCF10A cells (Supple-
mentary Figure S5). Strikingly, LASTR suppression in hy-
poxic MCF10A cells treated with LASTR GapmeRs fur-
ther decreased splicing efficiency and altered splicing pat-
terns (Figure 4G), indicating that stress-mediated LASTR
upregulation might counteract decreased splicing efficiency
under hypoxic stress. Given that LASTR depletion leads
to an increased association of SART3 with U4snRNP and
decreased splicing efficiency, we speculate that LASTR
might be implicated in the dissociation of SART3 from the
U4/U6snRNP complex during spliceosome recycling.
Intron retention mediated by LASTR loss decreases the fit-
ness of cancer cells
The impairment of the splicing machinery could be dele-
terious for cancer cells (44). Concordantly, suppression of
LASTR by inducible shRNAs impaired the ability of triple-
negative breast cancer cells to form 2D colonies (Figure 5A;
Supplementary Figure S6A, B) and inhibited anchorage-
independent growth in MDA-MB-231 cells (Figure 5B).
Induction of the expression of the LASTR shRNA also
blocked the growth of MDA-MB-231 under hypoxic con-
ditions (Figure 5C). To measure the effect of LASTR sup-
pression on tumor growth, we orthotopically implanted
MDA-MB-231/tet-shLASTR-2 cells into the breast pads
of immunodeficient mice. When the average volume of
the tumors reached 100 mm3, we induced the expression
of the shRNA against LASTR by adding doxycycline to
the drinking water. Of note, MDA-MB-231 xenografts
contained multiple hypoxic regions (Supplementary Fig-
ure S6C). Knockdown of LASTR dramatically inhibited
MDA-MB-231 xenograft growth despite the incomplete
depletion of LASTR (Figure 5D-F). Ki67 immunostain-
ing confirmed decreased proliferation in LASTR-depleted
MDA-MB-231 xenografts (Figure 5G). As DNA damage
also upregulates LASTR expression (Figure 2I), we also
investigated whether LASTR modified the irradiation re-
sponse of cancer cells. We found that LASTR knockdown
led to radio-sensitization of MCF10A-HER2 and MDA-
MB-468 cells (Figure 5H). Taken together, these results in-
dicate that LASTR fosters the fitness of cancer cells. (Figure
5D, E and Supplementary Figure S6C)
Dysregulated intron retention, which is a key process un-
derlying tumorigenesis, represented the most salient and
consistent feature across samples with decreased LASTR
expression. The analysis of the TCGA BRCA cohort also
showed that low LASTR expression was associated with
increased intron retention (Figure 6A). Therefore, we ex-
plored whether decreased cell fitness triggered by LASTR
depletion could be caused by aberrant intron retention.
We observed an extremely low correlation between PIR
changes in the analyzed models, indicating that there was no
overlap in significant intron retention events between differ-
ent model systems (Supplementary Figure S6D). Nonethe-
less, we noticed that highly expressed genes have a stronger
negative correlation with PIR changes when compared to
genes with low expression (Supplementary Figure S6E).
This indicates that highly expressed genes are more prone
to intron retention. Importantly, core fitness genes, which
are either essential genes or genes that promote cell prolif-
eration (45), have a significantly higher expression level in
breast cancer cells than the STOP genes that negatively reg-
ulate cell growth (46) (Supplementary Figure S6F). Con-
sistently to these observations, we found a significant en-
richment for core fitness genes among the genes with signif-
icantly increased intron retention in cells with either sup-
pressed SART3 or LASTR expression and in the TCGA
samples with low LASTR expression (Figure 6B–D). We
also observed a similar enrichment for core fitness genes
among the genes with significantly increased intron reten-
tion in MCF10A cells depleted for LASTR under hypoxic
conditions (Figure 6E).
Intron retention leads to downregulation of gene expres-
sion through the nonsense-mediated decay pathway (42,47).
We suggested that LASTR loss may reduce the fitness of
cancer cells by affecting the splicing efficiency and down-
regulating expression of multiple core fitness genes. In fact,
global analyses of mRNA and protein expression upon
LASTR depletion in MDA-MB-231 cells demonstrated
that the core fitness genes with significantly increased in-
tron retention were downregulated at both mRNA and pro-
tein levels in LASTR-suppressed MDA-MB-231 cells (Fig-
ure 6F, G). RT-qPCR experiments confirmed increased in-
tron retention and decreased expression of several core fit-
ness genes, such as HAUS5, TONSL, NDOR1, PSMG1 and
HNRNPH1, upon LASTR suppression (Figure 6H, I), sug-
gesting that concurrent downregulation of multiple core fit-
ness genes leads to decreased growth of LASTR-depleted
cells. Taken together, LASTR fosters fitness of cancer cells





Figure 4. LASTR depletion leads to widespread intron retention. (A) Histogram showing the distributions of differences in percent of intron retention
(PIR) and exon skipping (PSI) events in MDA-MB-231 expressing shGFP or shSART3-2. (B) Histogram showing the distributions of differences in percent
of intron retention (PIR) and exon skipping (PSI) events in MCF10A cells transfected with Scramble GapmeR or LASTR GapmeRs 1 and 2. (C) RT-qPCR
analysis of LASTR expression in MDA-MB-231 cells infected with tetracycline-inducible shRNAs against LASTR, untreated or treated with doxycycline
(1 g/ml, 8 days). Data are presented as mean ± s.e.m.; P-value was determined by a two-sided t-test, n = 3. (D–F) Histograms showing the distribution
of differences in percent of intron retention (PIR) and exon skipping (PSI) in MDA-MB-231 cells infected with tetracycline-inducible shRNAs against
LASTR, untreated or treated with doxycycline (1 g/ml, 8 days). (G) Histogram showing the distribution of differences in percent of the indicated splicing
events in hypoxic (1% O2, 48 h) MCF10A cells transfected with Scramble GapmeR or LASTR GapmeRs 1 and 2. (A, B, D–G) The number of identified
intron retaining and exon skipping events is shown. P-value was determined by Binomial test.
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Figure 5. LASTR fosters cell fitness under stress conditions. (A) 2D colony formation of the indicated cell lines untreated and treated with doxycycline
(1 g/ml). Representative images of 2D colonies and quantification of the colony number. P-values were determined by two-tailed t-tests, n = 3. (B)
Anchorage-independent growth of the indicated cell lines untreated and treated with doxycycline (1 g/ml). P-values were determined by two-tailed
t-tests, n = 3. (C) Cell growth of hypoxic MDA-MB-231/tet-shLASTR-2 cells untreated and treated with doxycycline (1 g/ml) as measured by the
CellTiter-Glo assay. Data are presented as mean ± s.e.m.; P-value was determined by two-way ANOVA, n = 3. (D) Tumor growth of MDA-MB-231/tet-
shLASTR-2 xenografts. Cells were implanted into the breast pads of immunodeficient mice. When the average tumor volume reached 100 mm3, expression
of the shRNA against LASTR was induced by adding doxycycline to the drinking water (2 mg/ml). Data are presented as mean ± s.e.m.; P-value was
determined by two-way ANOVA, n = 9. (E) Tumor weight of MDA-MB-231/tet-shLASTR-2 xenografts, untreated or treated with doxycycline (2 mg/ml)
at the end point. Data are presented as mean ± s.e.m.; P-value was determined by a two-tailed t-test. (F) RT-qPCR analysis of LASTR expression in
MDA-MB-231/tet-shLASTR-2 xenografts. Data are presented as mean ± s.e.m.; P-value was determined by a two-tailed t-test. (G) Ki67 immunostaining
of MDA-MB-231/tet-shLASTR-2 xenografts. Scale bar, 100 m. Data are presented as mean ± s.e.m.; P-value was determined by a two-tailed t-test. (H)
Colony formation assay of MCF10A-HER2 and MDA-MB-468 cells after exposure to increasing doses of ionizing radiation. The cells were pre-treated
with the indicated GapmeRs 24 h prior irradiation. Survival is presented as percentage ± s.e.m. of colonies formed relative to untreated cells; P-values were
determined by two-tailed t-tests, n = 3.
by inhibiting intron retention and downregulating expres-
sion of essential genes and could serve as a potential target
for anti-cancer therapy.
DISCUSSION
Alternative pre-mRNA splicing is an essential cellular pro-
cess, which enables multi-exonic genes to generate diverse
mRNA isoforms. This shapes the transcriptome size and
complexity and eventually leads to increased proteome di-
versity. A growing number of lncRNAs have been reported
to regulate splicing by different mechanisms. lncRNAs such
as MALAT1 or asFGFR2 affect the splicing output of tar-
get genes by modulating chromatin structure. Natural anti-
sense transcripts affect splicing by forming RNA-RNA du-
plexes with pre-mRNA. By interacting with specific splic-







Figure 6. LASTR loss declines fitness of cancer cells due to decreased expression of essential genes. (A) Histograms showing the distribution of differences
in percent of significant intron retention (PIR) in TCGA BRCA tumors with low or high LASTR expression (n = 547). The number of differentially intron
retaining genes is shown. P-values were determined by Binomial tests. 25th and 75th percentiles were used to define LASTR high and low expression in the
TCGA samples. (B–E) Genes showing increased intron retention in cells with suppressed SART3 or LASTR expression or in the TCGA BRCA samples
with low LASTR expression were compared to the lists of core fitness genes (45) or STOP genes (46) using Fisher’s exact test. 25th and 75th percentiles
were used to define LASTR high and low expression in the TCGA BRCA samples. (F) Gene set enrichment analysis of differentially expressed mRNAs in
MDA-MB-231/tet-shLASTR-2 untreated and treated with doxycycline (1 g/ml, 8 days) among the core fitness genes with significantly increased intron
retention. (G) Gene set enrichment analysis of differentially expressed proteins in MDA-MB-231/tet-shLASTR-2 untreated and treated with doxycycline
(1 g/ml, 8 days) among the core fitness genes with significantly increased intron retention. (H, I) RT-qPCR analysis of intron retention/exon expression
and mRNA expression levels of the indicated transcripts in MDA-MB-231/tet-shLASTR-2 untreated or treated with doxycycline (1 g/ml, 8 days). Data
are presented as mean ± s.e.m.; P-value was determined by a two-sided t-test, n = 3.
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ing factors, lncRNAs could affect their subcellular localiza-
tion, posttranslational modification, and activity (reviewed
in (48).
Here, we found that LASTR regulates splicing efficiency
by binding and regulating SART3, a recycling factor of
the splicing machinery. Specifically, LASTR loss regu-
lates the interaction of SART3 with the U4snRNP and
U6snRNP. Given that LASTR depletion increases the asso-
ciation of SART3 with the snRNP, it is likely that LASTR
might promote dissociation of SART3 from a transient
SART3-U4/U6snRNP complex. Studies of the yeast ho-
molog of SART3, Prp24, propose a model in which Prp24
first interacts with U6snRNP and facilitates its association
with U4snRNP through partial U4/U6snRNA annealing,
but then dissociates from a transient Prp24-U4/U6snRNP
complex to allow further spliceosome assembly. Impor-
tantly, Prp24 binds more tightly to the annealed U4/U6
complex than the U6 snRNP to stabilize the annealed prod-
uct, suggesting that additional factors are required to dis-
place Prp24 from U4/U6 di-snRNP (49,50). We could spec-
ulate that LASTR may serve as such a factor in human
cells.
Depletion of LASTR leads to splicing defects. The im-
pairment of the splicing machinery itself could be benefi-
cial for anticancer therapy as it can have deleterious effects
for cancer cells due to general splicing dysregulation. For
instance, it has been shown that small natural molecules
called pladienolides (SSA and E7107), that specifically tar-
get SF3B, a heptameric protein complex of the spliceosomal
U2snRNP, can inhibit cancer cell proliferation and induce
tumor growth regression in xenograft models due to the in-
duction of defective pre-mRNA splicing (51). Interestingly,
the same effect was accomplished using siRNA treatment
against SF3B (52).
GapmeR-mediated LASTR depletion induces splicing
defects in multiple genes that are essential for cancer cells,
thereby specifically affecting cancer cell fitness. Moreover, in
an immune competent environment, intron retention may
generate neoantigens that could help the clearance of the
tumor by the immune system and/or be used for vaccine
production (53). Antisense oligonucleotides have already
been utilized to induce defective splicing of some essen-
tial genes, e.g. in the case of a splicing switch of STAT3
to STAT3 mRNA isoform, which leads to cancer cell
death and tumor regression in a xenograft model (54). An-
tisense oligonucleotide–mediated skipping of exon 6 de-
creases MDM4 abundance, inhibits melanoma growth, and
enhances sensitivity to MAPK-targeting therapeutics (55).
These observations further strengthen the idea of using
LASTR inhibition as a suitable drug target in breast can-
cer treatment. Considering that LASTR overexpression
occurs not only in breast cancer but also in the major-
ity of epithelial cancers, this points towards more broad
applications of LASTR targeted therapy. Moreover, as
LASTR suppression induces radio-sensitization of cancer
cells, these findings open new prospects for the design of
a beneficial combinatorial therapeutic approach in cancer
therapy.
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